

Elbit Medical Technologies

Development update

Gamida hits on Phase III

Elbit Medical's holding Gamida Cell [recently](#) reported data from its 125-patient [Phase III study](#) of omidubichel in patients with haematological malignancies undergoing bone marrow transplants. The median time to neutrophil engraftment was 12 days for omidubichel patients compared to 22 days for those receiving standard umbilical cord blood ($p < 0.001$). Gamida Cell expects to initiate the rolling biologic licence application (BLA) submission in Q420 and launch in 2021.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/18	35.0	26.8	0.12	0.0	N/A	N/A
12/19	16.8	(21.2)	(0.09)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Omidubichel Phase III data positive

Gamida Cell reported data from its 125-patient Phase III study of omidubichel in patients with haematological malignancies undergoing bone marrow transplants. The median time to neutrophil engraftment was 12 days for omidubichel patients compared to 22 days for those receiving standard umbilical cord blood ($p < 0.001$). Additionally, among patients who were transplanted per protocol, 96% of those who received omidubichel achieved successful neutrophil engraftment, compared to 88% of those receiving standard umbilical cord blood.

Gamida raises \$69m in gross proceeds

Following the positive Phase III data, Gamida Cell made an offering of 15.3m shares at \$4.50 per share for a total of \$69m in gross proceeds. The company estimates that it is now fully funded into H221. Additionally, Elbit Medical sold 312,000 shares of Gamida in May and continue to hold approximately 2.4m shares of the company. Following the stock sales and the dilution from the offering, Elbit Medical's fully diluted stake in Gamida Cell has been reduced from approximately 7% to 4.1%.

Cash boost from InSightec stake sale

The successful sale of most of its InSightec stake provided Elbit with \$102.2m in cash. The company used part of the proceeds in Q120 to repurchase 133.3m shares for \$38m and will use most of the remainder of the cash for either the payment or repurchase of debt.

Valuation: NIS208.5 or NIS2.12 per share

We have reduced our valuation from NIS229.7m or NIS2.34 per share to NIS208.5m or NIS2.12 per share. This is mainly due to a reduction in net cash as well as a change in the value of the Gamida stake, which decreased due to both the dilution from the Gamida offering and Elbit Medical selling a portion of its stake. The reduction in the value of the Gamida offering was partially offset by an increase in the probability of success for omidubichel from 50% to 70% following the Phase III data.

Pharma & biotech

23 June 2020

Price* **NIS0.92**
Market cap **NIS91m**

*Priced at 19 June 2020

NIS3.50/US\$

Net cash (\$m) at 31 March 2020 + Gamida sale + debt repurchase 16.4

Shares in issue 98.1m

Free float 65%

Code EMTC

Primary exchange TASE

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs (17.4) 27.0 11.1

Rel (local) (15.8) 6.8 17.0

52-week high/low NIS1.4 NIS0.7

Business description

Elbit Medical Technologies is an Israeli biomedical and healthcare technology group. Its portfolio of two companies is focused on medical devices and therapeutics: InSightec, which develops and markets the ExAblate platform for non-invasive thermal tissue ablation, and Gamida Cell, which is developing a universal bone marrow transplant.

Next events

Rolling BLA submission for omidubichel Q420

Analysts

Maxim Jacobs +1 646 653 7027

Wiktoria O'Hare +1 646 653 7028

healthcare@edisongroup.com
[Edison profile page](#)

Positive omidubicel Phase III data

Positive data were recently reported for Gamida Cell's 125-patient Phase III study of omidubicel in patients with haematological malignancies. The median time to neutrophil engraftment was 12 days for omidubicel patients compared to 22 days for those receiving standard umbilical cord blood ($p < 0.001$). Additionally, among patients who were transplanted per protocol, 96% of those who received omidubicel achieved successful neutrophil engraftment, compared to 88% of those receiving standard umbilical cord blood.

As a reminder, omidubicel, which is this company's lead asset, expands umbilical cord blood (UCB) cell grafts *ex vivo* and enriches the specific subpopulation of stem and progenitor cells to treat haematological malignancies such as leukaemia and lymphoma. Essentially, CD133+ cells selected from a single unit of UCB are cultured for approximately three weeks in nicotinamide and are then cryopreserved until they are transplanted into the intended patients. This expansion of stem and progenitor cells is expected to provide a substantial advantage over a single UCB graft. The use of UCB for bone marrow transplantation (BMT) is generally limited by the minimal number of stem and progenitor cells. By expanding these cells, the omidubicel process seeks to provide a more viable alternative to BMT in cancer patients and only partial genetic matching is needed (ie a minimum requirement of four out of six human leukocyte antigen biomarkers). The registrational trial investigated the ability of omidubicel to provide a graft with an ample number of cells that have fast and vigorous *in vivo* neutrophil- and platelet-producing potential to improve transplantation outcomes (as low UCB cell dose is associated with delayed engraftment and poor outcomes). Gamida Cell expects to initiate the rolling BLA submission in Q420 and launch in 2021.

Gamida Cell ended Q120 with \$40.3m in cash and marketable securities. In May, following the release of the Phase III data, Gamida Cell completed an offering of 15.3m shares (including the underwriters' over-allotment options) at \$4.50 per share for a total of \$69m in gross proceeds. Gamida Cell has guided for a \$60–70m cash outflow for operating activities in 2020 and expects its current resources (following the offering) to fund its operations into H221. Following the stock sales and the dilution from the offering, Elbit Medical's fully diluted stake in Gamida Cell has been reduced from approximately 7% to 4.1%.

Valuation

We have reduced our valuation from NIS229.7m or NIS2.34 per share to NIS208.5m or NIS2.12 per share. This is mainly due to a reduction in net cash as well a change in the value of the Gamida stake, which decreased due to both the dilution from the Gamida offering and Elbit Medical selling a portion of its stake. The reduction in the value of the Gamida offering was partially offset by an increase in the probability of success for omidubicel from 50% to 70% following the Phase III data.

Exhibit 1: Elbit Medical valuation table

Product	Setting	Status	Launch	Peak sales (\$m)	Probability of success	Royalty rate	rNPV (\$m)	% owned by Elbit Medical (fully diluted)	Elbit Medical rNPV (\$m)
InSightec	MRgFUS (for gynaecology, oncology, neurology indications)	Market	Market	583	100%	100%	723	2.8%	20.2
Gamida Cell	Leukemia (AML, ALL, CML, CLL)	Phase III	2021	370	70%	100%	547	4.1%	22.4
Portfolio total (\$m)									42.7
Net cash (as of 31 March 2020 + net proceeds of Gamida share sale + debt repurchase) (\$m)									16.4
Overall valuation									59.1
Shekel/dollar conversion rate									3.5
Overall valuation in shekels (NISm)									208.5
Shares outstanding (m)									98.1
Per share (NIS)									2.12

Source: Edison Investment Research, Elbit Medical Technologies

Financials

Elbit Medical recently announced its Q120 financial results. Net income was \$118.5m, mainly due to profits stemming from the sale of its InSightec stake. General and admin costs for the period were \$0.3m, which includes management fees, professional services and other related expenses. The company had cash, cash equivalents, short-term deposits and restricted cash of \$62.2m at 31 March 2020 and \$47.8m in debt (which includes \$1.6m in fair value for the bond conversion component). Since the end of the quarter, the company raised \$2m by selling part of its stake in Gamida Cell and in June it repurchased debt with NIS1.9m par value for NIS2.3m. We outline historical financials in Exhibit 2. Please note we continue not to provide financial forecasts at this time.

Exhibit 2: Financial summary

	US\$'000s	2018	2019
Year end 31 December		IFRS	IFRS
PROFIT & LOSS			
Revenue		34,951	16,803
Cost of Sales		0	0
Gross Profit		34,951	16,803
R&D expenses		0	0
SG&A expenses		(918)	(470)
Other expenses		0	(15,937)
EBITDA		34,033	396
Operating Profit (before amort. and except.)		34,033	396
Intangible Amortisation		0	0
Exceptionals		0	0
Operating Profit		34,033	396
Other		0	(14,847)
Net Interest		(7,212)	(6,769)
Profit Before Tax (norm)		26,821	(21,220)
Profit Before Tax (FRS 3)		26,821	(21,220)
Tax		0	0
Profit After Tax (norm)		26,821	(21,220)
Profit After Tax (FRS 3)		26,821	(21,220)
Average Number of Shares Outstanding (m)		231.5	231.5
EPS - normalised (\$)		0.12	(0.09)
EPS - FRS 3 (\$)		0.12	(0.09)
Dividend per share (\$)		0.0	0.0
BALANCE SHEET			
Fixed Assets		24,233	11,548
Intangible Assets		23,016	11,548
Tangible Assets		0	0
Other		1,217	0
Current Assets		3,797	2,248
Stocks		0	0
Debtors		11	35
Cash		3,786	2,213
Other		0	0
Current Liabilities		(1,526)	(1,522)
Creditors		(1,526)	(1,522)
Short term borrowings		0	0
Short term leases		0	0
Other		0	0
Long Term Liabilities		(41,998)	(48,961)
Long term borrowings		(39,030)	(46,661)
Long term leases		0	0
Other long-term liabilities		(2,968)	(2,300)
Net Assets		(15,494)	(36,687)
CASH FLOW			
Operating Cash Flow		(499)	(571)
Tax		0	0
Capex		0	0
Acquisitions/disposals		0	0
Financing		0	0
Dividends		0	0
Other		(4,113)	2,165
Net Cash Flow		(4,612)	1,594
Opening net debt/(cash)		42,383	35,244
HP finance leases initiated		(6,835)	(2,542)
Other		18,586	(8,256)
Closing net debt/(cash)		35,244	44,448

Source: Company accounts

General disclaimer and copyright

This report has been commissioned by TASE and prepared and issued by Edison, in consideration of a fee payable by TASE. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Israel

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively "the Scheme", "TASE", "Participant" and/or "Participants"). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively "Edison Israel" and "Edison"), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter "the Agreement"), regarding the Participants and according to the Scheme (hereinafter "the Analysis" or "Analyses"). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter "the ISA") website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of \$35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities' regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
1,185 Avenue of the Americas
3rd Floor, New York, NY 10036
United States of America

Sydney +61 (0)2 8249 8342
Level 4, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia

Tel Aviv +44 (0)20 3734 1007
Azrieli Centre, Triangle Building
38th Floor, Tel Aviv, 4676652
Israel